Health
J&J Buys Firefly Bio for Cancer Research
Johnson & Johnson acquired startup Firefly Bio for $1 billion to advance its research in KRAS inhibitors, a promising area of cancer treatment.
Coverage timeline — 1 article
STAT News
Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.
2026-06-08 13:17 UTC